All In Biotech

Free tool

FAERS Monitor: Defitelio

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208114 or its brand name (Defitelio, Defibrotide Sodium). Reports on generic versions are filed under their own applications.

Reports

3,584

Serious

3,018

84% of reports

Hospitalization

763

Death reported

1,751

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use1,245
  • venoocclusive disease565
  • death465
  • venoocclusive liver disease347
  • multiple organ dysfunction syndrome343
  • intentional product use issue198
  • hypotension160
  • haemorrhage157
  • acute graft versus host disease140
  • gastrointestinal haemorrhage123
  • sepsis121
  • renal failure104
  • septic shock104
  • disease progression99
  • cystitis haemorrhagic93

Reports by year received

View as table
YearReports
201668
2017126
2018601
2019505
2020503
2021198
2022474
2023617
2024293
2025120
202679

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,575 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
venoocclusive diseaseSignal5651709.71566.0746,081
venoocclusive liver diseaseSignal347443.5399.6142,053
acute graft versus host diseaseSignal140185.1157.024,681
cystitis haemorrhagicSignal93138.6113.112,277
multiple organ dysfunction syndromeSignal34371.965.023,659
septic shockSignal10414.111.61,248
intentional product use issueSignal19813.311.62,243
haemorrhageSignal1578.87.61,085
gastrointestinal haemorrhageSignal1238.67.3826
off label useSignal1,2458.48.08,391
sepsisSignal1216.45.3545
disease progressionSignal994.94.0306
hypotensionSignal1604.74.0464
renal failureSignal1044.63.8291
deathSignal4653.22.9717

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.